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ABSTRACT
OBJECTIVE.Increasing access to highly active antiretroviral therapy to reach all those
in need in developing countries (scale up) is slowly expanding to HIV-positive
children, but documented experience remains limited. We aimed to describe the
clinical, immunologic, and virologic outcomes of pediatric patients with 12
months of highly active antiretroviral therapy in 2 routine programs in Cambodia.
METHODS.Between June 2003 and March 2005, 212 children who were younger
than 13 years started highly active antiretroviral therapy. Most patients started a
standard ﬁrst-line regimen of lamivudine, stavudine, and nevirapine, using split
adult ﬁxed-dosage combinations. CD4 percentage and body weight were moni-
tored routinely. A cross-sectional virologic analysis was conducted in January
2006; genotype resistance testing was performed for patients with a detectable
viral load.
RESULTS.Mean age of the subjects was 6 years. Median CD4 percentage at baseline
was 6. Survival was 92% at 12 months and 91% at 24 months; 13 patients died,
and 4 were lost to follow-up. A total of 81% of all patients had an undetectable
viral load. Among the patients with a detectable viral load, most mutations were
associated with resistance to lamivudine and non–nucleoside reverse-transcriptase
inhibitor drugs. Five patients had developed extensive antiretroviral resistance.
Being an orphan was found to be a predictor of virologic failure.
CONCLUSIONS.This study provides additional evidence of the effectiveness of integrat-
ing HIV/AIDS care with highly active antiretroviral therapy for children in a
routine setting, with good virologic suppression and immunologic recovery
achieved by using split adult ﬁxed-dosage combinations. Viral load monitoring and
HIV genotyping are valuable tools for the clinical follow-up of the patients.
Orphans should receive careful follow-up and extra support.
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CCESS TO ANTIRETROVIRAL treatment for patients
with AIDS in resource-limited settings has in-
creased dramatically in the past few years, with 1.6
million currently estimated to be receiving treatment.
Despite these efforts, however, 5% of the 800 000
children who are in need of antiretroviral therapy are
receiving it.1 Of the 39.5 million people who were esti-
mated to be living with HIV/AIDS in 2006, 2.3 million
were children who were younger than 15; more than
half a million children died of HIV/AIDS that year.2 In
the West, good outcomes are achieved for children who
are on highly active antiretroviral therapy (HAART),3–7
and studies indicate that similar outcomes can be
achieved in resource-limited settings.8–11 However, doc-
umented experience of treating large numbers of chil-
dren remains limited.
Cambodia is 1 of the poorest countries in Asia, rank-
ing 130th on the human development index with an
annual gross domestic product per capita of $2078.12
Generally the prevention response has been good in
Cambodia, with HIV prevalence falling from 3% in 1997
to 1.9% in 2003. However, national efforts to prevent
mother-to-child transmission only began in 2003.
Antiretroviral therapy has been provided in Cambo-
dia since 2001. By December 2005, government and
nongovernmental actors supported 12 000 patients
with HAART, which allowed the country to reach its
World Health Organization (WHO) 3 by 5 target, which
aims to start HAART for 3 million patients with AIDS
worldwide by the end of 2005. Children have beneﬁted
from treatment since it has been available, with Me ´-
decins Sans Frontie `res (MSF) and the Cambodian Min-
istry of Health providing HAART to children since 2002.
This was given additional priority in 2004, when the
Ministry of Health released a policy package of treatment
guidelines, training, and drug supply devoted to the
management of pediatric HIV. This article provides out-
comes of providing HAART for 212 children within a
cohort of 800 HIV-positive children who were under
care in 2 district hospitals in Cambodia.
METHODS
StudySitesandPatients
Outcome data were pooled from 2 district hospitals:
Angkor Hospital for Children in Siem Reap province
(population 700 000) and Takeo district hospital in
Takeo province (population 800 000). Angkor Hospital
for Children is a charity-run 50-bed pediatric hospital
that started to provide care for HIV-positive children in
collaboration with MSF in February 2003. The Takeo
district hospital is a 164-bed public referral hospital that
started providing HIV care for children in February 2004,
also with support from MSF. Both hospitals attract chil-
dren from across the province as well as from neighbor-
ing provinces. Services in both sites are comparable and
are provided primarily by Cambodian medical staff. The
support of MSF was limited to technical assistance, the
supply of most of the medicines, and the organization of
the laboratory tests.
By March 2006, a total of 805 HIV-positive children
(478 in Siem Reap and 327 in Takeo) had been enrolled
in these 2 sites, 428 of whom had started HAART. Of the
remainder, 82 (10%) patients were eligible for HAART
but had died or were lost to follow-up before initiation
and 295 (37%) did not meet eligibility criteria for
HAART (see “Antiretroviral Therapy” below). All chil-
dren at both sites who were aged 13 years and on
HAART for 12 months were included in a cross-sec-
tional evaluation of the virologic status, with an inten-
tion-to-treat analysis of the virologic efﬁcacy performed
on all children who started HAART between June 2003
and March 2005.
AntiretroviralTherapy
Criteria to commence HAART followed national guide-
lines: HIV-positive status (serology or reverse transcrip-
tase polymerase chain reaction for children younger
than 18 months) and CD4 count (20% for children
younger than 5 years or 200 cells per mL for children
older than 5 years). The majority of the patients started
on a standard ﬁrst-line regimen of stavudine, lamivu-
dine, and nevirapine, as recommended by the WHO.13
Zidovudine and efavirenz were used as alternatives in
case of intolerance or interaction with other drugs. Adult
generic ﬁxed-dosage combinations (FDCs) were used for
the children who were on the ﬁrst-line regimen: before
December 2003, GPOvir (GPO, Bangkok Thailand) was
used; patients were then switched to Triviro (Ranbaxy,
Dewas, India) on prequaliﬁcation of this treatment.14
Tablets were cut in half to obtain the most appropriate
dosages, and for some body weights, nevirapine syrup
was added to achieve the correct dosage, according to a
standardized drug-dosage table.15 For the patients in
whom treatment failure was diagnosed, an individual
evaluation was made to decide on a switch to a second-
line HAART regimen. All patients received at least 3
HAART-preparation counseling sessions before com-
mencing the treatment. For younger children, counsel-
ing was given in the presence of the parents or the
caregivers; for older children, a part of the sessions were
given to the patients alone. Disclosure of HIV status was
not a condition to start HAART, but the counselors de-
veloped an individual plan for each patient to follow a
process of disclosure. Adherence to HAART was not
systematically recorded, but several steps were taken to
provide support for adherence. After commencement of
HAART, adherence support was provided by the coun-
selors at every visit to the clinic. Home visits were con-
ducted for patients who arrived late for appointments or
were suspected of needing more social support (al-
though this was not always feasible for all patients who
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afford the travel to the clinics, ﬁnancial support for
transportation cost was provided.
Clinical,Immunologic,andVirologicEvaluation
Body weight was measured at every visit. CD4 cell count
was measured at baseline and every 6 months after
HAART initiation by ﬂow cytometry (Facscount; Becton
Dickinson, San Jose, CA). For children who were
younger than 5 years, CD4% was used as the standard
follow-up indicator; for the older children, both CD4%
and the absolute CD4 cell count were used as recom-
mended by the WHO.13 Hemoglobin and alanine amin-
otransferases were measured at week 2; months 1, 2, 3,
and 6; and every 6 months thereafter to monitor for
toxicity.
Between February 2006 and June 2006, viral load
measurements were performed together with routine
CD4 tests (ﬂow cytometry, Facscount) for all patients
who were on HAART for 12 months. HIV-1 RNA viral
load was quantiﬁed by real-time reverse transcriptase
polymerase chain reaction as developed by the French
“Agence Nationale de Recherche sur le SIDA et les He ´pa-
tites Virales.” For patients with a detectable viral load (ie,
400 copies per mL), a genotype resistance test was
done. For the genotype resistance study, viral RNA was
extracted (QIAampViral RNA minikit; Qiagen, Hamburg,
Germany) and ampliﬁed for reverse transcriptase genes,
sequenced automatically (CEQ DTCS Quick start kit;
Beckman Coulter, Fullerton, CA), and corrected manu-
ally using CEQ 8000 software (Beckman Coulter). Nu-
cleotide sequences were compared against known refer-
ence strains of group M of the HIV-1 gene bank (www.
hiv-web.lanl.gov). Genotype resistance interpretation
was performed according to algorithms developed by the
“Agence Nationale de Recherche sur le SIDA et les He ´pa-
tites Virales” (www.hivfrenchresistance.org) and the In-
ternational AIDS Society (www.iasusa.org). All viral
load and genotype resistance tests were performed at the
Pasteur Institute (Phnom Penh, Cambodia).
This cohort evaluation received ethical approval of
the Angkor Hospital for Children ethics committee; all
patients were informed about the objectives of the lab-
oratory tests during the routine counseling sessions. The
results of all of the tests were made available to the
clinicians as soon as possible to guarantee optimal ben-
eﬁts for the patients.
StatisticalAnalysis
All data regarding medical background and follow-up of
patients were collected on FUCHIA 1.5 monitoring soft-
ware (Epicenter, Paris, France). The z score for weight
for height to evaluate growth was used from the WHO
(Geneva, Switzerland) reference curves. The probability
of survival and remaining in care was calculated with
Kaplan-Meier with all patients analyzed on an inten-
tion-to-treat basis. Patients who were alive and in care
or transferred out on March 31, 2006, were censored on
the date of their last visit before this date. Patients with
3 months’ delay with respect to the scheduled fol-
low-up visit were regarded as lost to follow-up. A sur-
vival analysis to estimate the probability of patients’
remaining in care was done with events (uncensored)
counted as patients who died or who were lost to follow-
up. Conﬁdence intervals (CIs) around the proportions of
patients whose treatment was successful or failing were
calculated with Mantel-Haenszel test with 95% limits.
Logistic regression analysis was used to identify factors
that were associated with virologic failure (viral load 
400 copies per mL). For all listed baseline factors, both
univariate and multivariate analyses were calculated. All
statistical analyses were performed by using Epi Info
2002 software (Centers for Disease Control and Preven-
tion, Atlanta, GA).
RESULTS
CharacteristicsoftheStudyPopulation
A total of 212 patients had started HAART between June
2003 and March 2005. Baseline characteristics are pre-
sented in Table 1. Sixteen patients had started HAART in
2003, 131 in 2004, and 65 in the ﬁrst quarter of 2005.
Median age at start of HAART was 6 years (interquartile
rang [IQR]: 4.2–7.9), and only 7 (3%) children were
younger than 18 months. The primary caregivers were
biological parents (64%); grandparents (30%); or rela-
tives, neighbors, or orphanages (6%). A total of 76
(36%) of the children were orphans. Only 8 (10.5%) of
the 76 orphans were cared for in a structured orphanage.
Median CD4% before starting HAART in all patients was
6% (IQR: 2.6–13.0), and the median absolute CD4
count for the children aged 5 years (n  134) was 100
cells per mL (IQR: 22–273). In January 2006, 193 of the
patients were alive and could be included in the cross-
sectional virologic evaluation.
TreatmentOutcomes
Of 212 children who had started HAART before March
2005, 13 had died, 4 were lost to follow-up, and 2 were
transferred to another treatment site. Tuberculosis was
responsible for 8 deaths; the remainder were attributed
to severe sepsis (2 deaths), pneumonia, bacterial men-
ingitis, and wasting syndrome. According to the survival
analysis, 92% of the children were alive and in care at 12
months and 91% at 24 months of treatment (Fig 1).
Median time on HAART of the patients who were alive
was 16.8 months (IQR: 13.9–21.2). Thirty-six (17%)
patients were on HAART for 24 months. Mean weight-
for-height z score increased by 0.81 to 0.78 (SD:
1.17) at 12 months of HAART. HAART was generally
well tolerated, with only 7 patients having to switch to
e1136 JANSSENS et al
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nevirapine (2), zidovudine (2), and stavudine (3).
Median CD4% gain at 12 months was 17.0% (IQR:
16.3%–30.7%); among the children who were older
than 5 years at that time (n  164), median CD4 cell
count gain from baseline was 490 cells per mL. Viral load
was measured for all 193 patients who were alive and on
HAART for 12 months. A total of 156 (81% [95% CI:
74%–85%]) of the samples showed an undetectable
viral load (400 copies per mL), 7 (3.7% [95% CI:
1.6%–7.5%]) of the patients had a viral load between
400 and 1000 copies per mL, and 30 (15.5% [95% CI:
11.0%–21.4%]) of the patients had a viral load of 1000
copies per mL.
In an intention-to-treat analysis, 156 of 212 (73.6%
[95% CI: 67.0%–79.0%]) of all patients who started
HAART before March 2005 had an undetectable viral
load. Of these, 36 had been on HAART for 24 months,
and among this subgroup, 24 (66.6% [95% CI: 50.0%–
80.0%]) had an undetectable viral load. The proportion
with an undetectable viral load in the intention-to-treat
analysis for this group was 24 of 38 (63.0% [95% CI:
47.0%–76.6%]). Of the 30 children with a viral load of
1000 copies, 16 (53%) were in immunologic failure at
the moment of the viral load according to the criteria of
the guidelines from the National Institutes of Health.16
In the analysis of baseline characteristics as predictors
of virologic failure (Table 2), being an orphan was found
to be a statistically signiﬁcant predictor of virologic fail-
ure (P  .001). For all 37 samples with a viral load of
400 copies per mL, genotype resistance testing was
performed. Genotyping could not be ampliﬁed in 1 case.
In 34 samples, at least 1 mutation was found. Of the 2
samples in which none was detected, viral loads were
16 637 and 689 copies per mL. Mutations in 31 of 34
patients showed a nucleoside reverse-transcriptase in-
hibitor (NRTI) mutation, the most common being M184
(n  26), D67 (n  7), T215 (n  7), and T69 and L210
(n  4). Twenty-seven patients had developed resistance
to lamivudine, 9 to zidovudine, and 11 to stavudine.
Resistance to abacavir was found in 4 patients, to teno-
fovir in 3 patients, and to didanosine in 3 patients.
Thirty-two of 34 had developed non–nucleoside reverse-
transcriptase inhibitor (NNRTI) resistance, 3 of them had
no NRTI resistance. Of 31 patients with NRTI resistance,
2 showed no NNRTI resistance.
DISCUSSION
The experience of these 2 pediatric HIV/AIDS care pro-
grams shows that antiretroviral therapy is feasible for
children at the district level in Cambodia, with very good
results obtained after 2 years on treatment. A total of
92% of patients were alive at 12 months, and median
CD4% rose from 6% at baseline to 25% at 12 months. A
cross-sectional survey of viral load of all patients who
were receiving HAART at 12 months showed that 81%
had an undetectable viral load using a threshold of de-
tection of 400 copies per mL as treated and 74% in
intention-to-treat analysis.
The proportion of patients who achieved virologic
success is equal to or better than all of the clinical trials
in Western settings before 2002 as summarized in a
review article by Van Rossum et al.17 Among the best
results cited in the review, 3 trials are comparable; they
report the proportion of patients with a viral load of
400 copies per mL at 48 to 72 weeks of HAART as
69%, 70%, and 87%, respectively, on a population as
treated. Only 1 result is available on an intention-to-
treat population, and that showed 61% with a viral load
of 400 copies per mL. In the comparison with the
results of our Cambodian cohort, it has to be acknowl-
edged, however, that in a number of these studies, no
patients were included that were naive to NRTI. The
outcomes in this study generally also compare favorably
TABLE1 BaselineCharacteristicsofCambodianChildreninTakeo
andSiemReapWhoStartedHAARTBeforeMarch2005
Characteristic Value
Demographics
All patients 212
Female,n(%) 94(44.4)
Age, median (IQR), y 6(4–7.9)
Clinicoimmunology
CDC stage at HAART initiation,n(%)
Stage N (asymptomatic),n(%) 20(9.5)
Stage A (mild),n(%) 55(26)
Stage B (moderate),n(%) 93(43.8)
Stage C (severe),n(%) 44(20.7)
Weight-for-heightzscore, meanSD 1.591.08
CD4 cells (all patients), median (IQR), % 6(2.6–13)
CD4 cells5% (all patients), % 84(40)
CD4 count (patients5 y), median (IQR),
cells per mL (n134)
100(22–273)
Initial antiretroviral treatment
D4T/3TC/NVP,n(%) 146(68.9)
D4T/3TC/EFV,n(%) 40(18.8)
AZT/3TC/NVP,n(%) 26(12.3)
Time on HAART, median (IQR), mo 16.8(13.9–21.2)
Social,n(%)
Geographic origin
From the same province as the clinic 90(42.4)
From another province 122(67.6)
Caregiver
At least 1 of the parents 136(64)
Orphans 76(36)
Grandparents as caregiver 63(30)
Other caregiver 13(6)
Outcomes,n(%)
Active in treatment 193(91)
Died 13(6.1)
Lost to follow-up 4(2)
Transferred to another treatment site 2(0.9)
Mortality rate, per person-year 4
CDC indicates Centers for Disease Control and Prevention; D4T, stavudine; 3TC, lamivudine;
NVP, nevirapine; EFV, efavirenz; AZT, zidovudine.
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limited contexts such as Thailand, Romania, and Ivory
Coast.8,10,11
The majority of patients in our cohort were treated
with split adult FDC of 2 NRTIs and 1 NNRTI, conﬁrming
other ﬁndings that good outcomes can be achieved with
this treatment strategy.18,19 It should be noted, however,
that this practice is a suboptimal interim strategy13 pend-
ing prequaliﬁcation of pediatric formulations of FDCs.
The majority of the patients were in an advanced stage of
HIV infection, similar to many settings where HIV/AIDS
care for children has been commenced. We also note
that the 2 different settings offer similar results, demon-
strating that a well-organized public hospital (Takeo)
with targeted support can achieve a quality of care equal
to a private, nonproﬁt setting. In Takeo, all consultations
and nursing support was done by Ministry of Health
hospital staff, and MSF provide psychosocial support and
technical support.
Being orphaned was found to lead to a greater risk for
virologic failure, and this is likely because of poorer
adherence support, although this cannot be said with
certainty given that adherence was not recorded system-
atically. Most of these orphans are cared for in the family
of the grandparents or neighbors. The results of this
evaluation should encourage paying a greater attention
to adherence support for this group, for example,
through more intensive home-based care, speciﬁc coun-
seling sessions for grandmothers, or the development of
better adapted tools and approaches for adherence sup-
port.
We are aware of 7 patients who had previous anti-
retroviral experience (purchased drugs from private
pharmacies or shared with their parents). All but 1 of
these developed virologic treatment failure. We do not
know for certain whether other children were also an-
FIGURE1
Survival of children who started HAART in Takeo and Siem Reap.
TABLE2 EffectsoftheBaselineCharacteristicsontheLikelihood
ThatPlasmaHIVRNAWouldbe>400CopiespermLAfter
>12MonthsofHAART
Characteristic RiskRatio(95%CI)
Univariate Multivariate
Age, y
6 1.00 —
6 1.200(0.580–2.480) —
Gender
Female 1.00 —
Male 1.900(0.910–4.100) 1.800(0.860–4.100)
Adjustedzscore for weight
(per unit increase)
0.867(0.612–1.230) —
CD4 %
5 1.00 —
5 0.685(0.330–1.400) —
CDC stage
All other stages 1.00 —
Stage C 1.700(0.560–5.280) —
Geographic origin
Patients from the same
province
1.00 —
Patients from outside the
province of the clinic
1.230(0.558–2.730) —
Caregiver
Children with at least 1
parent
1.00 —
Orphan 3.850(1.830–8.110) 3.800(1.800–8.000)
Regimen at start
AZT/3TC/NVP 1.00 —
D4T/3TC/NVP 1.180(0.315–4.450) —
D4T/3TC/EFV 1.110(0.411–2.970) —
Multivariatevalueswereonlyrepresentedwhenunivariatevaluesshowedasigniﬁcanteffectof
the baseline characteristic.
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the clinics, so it is not possible to calculate the treatment
success rate among antiretroviral-naive patients. In the
MSF cohorts of adult patients in Cambodia (5000 pa-
tients), 5% of all new patients are antiretroviral expe-
rienced, and a large proportion of pediatric patients have
parents on HAART, so it is possible that more pediatric
patients are antiretroviral experienced.
Sixteen of 30 patients with a viral load of 1000
copies per mL showed clear immunologic failure at the
last CD4 measurement. Previous studies have concluded
that CD4 monitoring is more appropriate than virologic
monitoring because a decreasing CD4 count is a better
predictor of disease progression.7 Early detection of
treatment failure is important to limit the selection of
resistance mutations, although it remains unclear at
which level of detectable viral load patients should be
switched.20
All but 1 patient with a viral load of 1000 copies per
mL had developed 1 resistance mutation indicating
failure to the ﬁrst-line HAART regimen. Seven patients
had developed a proﬁle of extensive resistance, leaving
very few options for a HAART regimen that could be
effective in achieving viral suppression. Five of these
patients were known to be antiretroviral experienced.
Five of the 30 patients in whom treatment failure was
detected had virus strains that were sensitive to only 1
drug in the suggested standard second-line regimen in
the 2006 WHO guidelines for infants and children.13
Three of these patients were known to be antiretroviral
experienced, which suggests that the use of a standard
second-line regimen will not be a good solution for all
patients, and an expanded formulary is needed.
There are several limitations to this study. First, al-
though a small group of patients have been on HAART
for at least 24 months, the overall time under HAART is
still short. Second, we do not have good information on
antiretroviral experience for all of the patients; neither
have we attempted to measure adherence in a system-
atic way. Third, only 7 children who started HAART at
younger than 18 months are included in this cohort
because of the unavailability of appropriate diagnostic
tools to diagnose HIV/AIDS in infants in the ﬁrst years of
the clinics’ activities, and only rarely did children with
suspected HIV infection reach the clinics before the age
of 1.
Despite these limitations, these ﬁndings provide clear
support for the feasibility of integrating pediatric care in
a HAART clinic at the district level. Viral load is a valu-
able tool for detecting early treatment failure, and geno-
typing is useful for choosing the best second-line regi-
men, particularly for treatment-experienced patients.
Orphans are at higher risk for developing treatment
failure and need extra attention and support.
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